Format

Send to

Choose Destination
Acta Myol. 2012 Dec;31(3):196-200.

Next generation sequencing (NGS) strategies for the genetic testing of myopathies.

Author information

1
Telethon Institute of Genetics and Medicine, Naples, Italy. vincenzo.nigro@unina2.it

Abstract

Next generation sequencing (NGS) technologies offer the possibility to map entire genomes at affordable costs. This brings the genetic testing procedure to a higher level of complexity. The positive aspect is the ease to cope with the complex diagnosis of genetically heterogeneous disorders and to identify novel disease genes. Worries arise from the management of too many DNA variations with unpredictable meaning and incidental findings that can cause ethical and clinical dilemmas. The technology of enrichment makes possible to focus the sequencing to the exome or to a more specific DNA target. This is being used to provide insights into the genetics underlying Mendelian traits involved in myopathies and to set up cost-effective diagnostic tests. This huge potential of the NGS applications makes likely that these will soon become the first approach in genetic diagnostic laboratories.

KEYWORDS:

NGS; Next generation sequencing; neuromuscular disorders

PMID:
23620651
PMCID:
PMC3631804
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center